Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Completed
Bayer
Phase 2
2010-02-01
The purpose of this research study is to determine the safety and activity of regorafenib in
participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved
therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug
that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important
to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both
imatinib and sunitinib work; however, regorafenib blocks certain additional signaling
pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested
in GIST participants before this research study.
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Completed
Brigham and Women's Hospital
Phase 2
2010-02-01
The purpose of this research study is to determine the safety and activity of regorafenib in
participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved
therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug
that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important
to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both
imatinib and sunitinib work; however, regorafenib blocks certain additional signaling
pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested
in GIST participants before this research study.
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Completed
Fox Chase Cancer Center
Phase 2
2010-02-01
The purpose of this research study is to determine the safety and activity of regorafenib in
participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved
therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug
that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important
to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both
imatinib and sunitinib work; however, regorafenib blocks certain additional signaling
pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested
in GIST participants before this research study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
